Primary  ||| S:0 E:8 ||| JJ
angiitis  ||| S:8 E:17 ||| NN
of  ||| S:17 E:20 ||| IN
the  ||| S:20 E:24 ||| DT
central  ||| S:24 E:32 ||| JJ
nervous  ||| S:32 E:40 ||| JJ
system  ||| S:40 E:47 ||| NN
Primary  ||| S:47 E:55 ||| JJ
angiitis  ||| S:55 E:64 ||| NN
of  ||| S:64 E:67 ||| IN
the  ||| S:67 E:71 ||| DT
central  ||| S:71 E:79 ||| JJ
nervous  ||| S:79 E:87 ||| JJ
system  ||| S:87 E:94 ||| NN
( ||| S:94 E:95 ||| -LRB-
PACNS ||| S:95 E:100 ||| NNP
)  ||| S:100 E:102 ||| -RRB-
was  ||| S:102 E:106 ||| VBD
first  ||| S:106 E:112 ||| RB
identified  ||| S:112 E:123 ||| VBN
half  ||| S:123 E:128 ||| PDT
a  ||| S:128 E:130 ||| DT
century  ||| S:130 E:138 ||| NN
ago ||| S:138 E:141 ||| RB
,  ||| S:141 E:143 ||| ,
but  ||| S:143 E:147 ||| CC
it  ||| S:147 E:150 ||| PRP
remains  ||| S:150 E:158 ||| VBZ
a  ||| S:158 E:160 ||| DT
rare  ||| S:160 E:165 ||| JJ
and  ||| S:165 E:169 ||| CC
challenging  ||| S:169 E:181 ||| JJ
disease ||| S:181 E:188 ||| NN
.  ||| S:188 E:190 ||| .
However ||| S:190 E:197 ||| RB
,  ||| S:197 E:199 ||| ,
important  ||| S:199 E:209 ||| JJ
advances  ||| S:209 E:218 ||| NNS
have  ||| S:218 E:223 ||| VBP
been  ||| S:223 E:228 ||| VBN
made  ||| S:228 E:233 ||| VBN
in  ||| S:233 E:236 ||| IN
the  ||| S:236 E:240 ||| DT
field  ||| S:240 E:246 ||| NN
of  ||| S:246 E:249 ||| IN
PACNS ||| S:249 E:254 ||| NNP
,  ||| S:254 E:256 ||| ,
mainly  ||| S:256 E:263 ||| RB
through  ||| S:263 E:271 ||| IN
recently  ||| S:271 E:280 ||| RB
published  ||| S:280 E:290 ||| VBN
retrospective  ||| S:290 E:304 ||| JJ
analyses  ||| S:304 E:313 ||| NNS
of  ||| S:313 E:316 ||| IN
large  ||| S:316 E:322 ||| JJ
groups  ||| S:322 E:329 ||| NNS
of  ||| S:329 E:332 ||| IN
PACNS  ||| S:332 E:338 ||| NNP
patients ||| S:338 E:346 ||| NNS
,  ||| S:346 E:348 ||| ,
and  ||| S:348 E:352 ||| CC
the  ||| S:352 E:356 ||| DT
consideration  ||| S:356 E:370 ||| NN
of  ||| S:370 E:373 ||| IN
reversible  ||| S:373 E:384 ||| JJ
cerebral  ||| S:384 E:393 ||| JJ
vasoconstriction  ||| S:393 E:410 ||| JJ
syndrome  ||| S:410 E:419 ||| NN
as  ||| S:419 E:422 ||| IN
a  ||| S:422 E:424 ||| DT
distinct  ||| S:424 E:433 ||| JJ
entity ||| S:433 E:439 ||| NN
.  ||| S:439 E:441 ||| .
Clinical  ||| S:441 E:450 ||| JJ
manifestations  ||| S:450 E:465 ||| NNS
of  ||| S:465 E:468 ||| IN
PACNS  ||| S:468 E:474 ||| NNP
are  ||| S:474 E:478 ||| VBP
variable  ||| S:478 E:487 ||| JJ
and  ||| S:487 E:491 ||| CC
non-specific ||| S:491 E:503 ||| JJ
.  ||| S:503 E:505 ||| .
Even  ||| S:505 E:510 ||| RB
though  ||| S:510 E:517 ||| IN
neuroimaging  ||| S:517 E:530 ||| NNS
can  ||| S:530 E:534 ||| MD
be  ||| S:534 E:537 ||| VB
suggestive  ||| S:537 E:548 ||| VBN
of  ||| S:548 E:551 ||| IN
vasculitis ||| S:551 E:561 ||| NN
,  ||| S:561 E:563 ||| ,
only  ||| S:563 E:568 ||| RB
a  ||| S:568 E:570 ||| DT
leptomeningeal  ||| S:570 E:585 ||| JJ
biopsy  ||| S:585 E:592 ||| NN
can  ||| S:592 E:596 ||| MD
definitively  ||| S:596 E:609 ||| RB
confirm  ||| S:609 E:617 ||| VB
vasculitis ||| S:617 E:627 ||| NNS
.  ||| S:627 E:629 ||| .
However ||| S:629 E:636 ||| RB
,  ||| S:636 E:638 ||| ,
a  ||| S:638 E:640 ||| DT
brain  ||| S:640 E:646 ||| NN
sample  ||| S:646 E:653 ||| NN
is  ||| S:653 E:656 ||| VBZ
taken  ||| S:656 E:662 ||| VBN
in  ||| S:662 E:665 ||| IN
less  ||| S:665 E:670 ||| JJR
than  ||| S:670 E:675 ||| IN
half  ||| S:675 E:680 ||| PDT
the  ||| S:680 E:684 ||| DT
patients  ||| S:684 E:693 ||| NNS
and  ||| S:693 E:697 ||| CC
cannot  ||| S:697 E:704 ||| JJ
further  ||| S:704 E:712 ||| JJ
help  ||| S:712 E:717 ||| NN
to  ||| S:717 E:720 ||| TO
distinguish  ||| S:720 E:732 ||| VB
between  ||| S:732 E:740 ||| IN
PACNS  ||| S:740 E:746 ||| NNP
and  ||| S:746 E:750 ||| CC
secondary  ||| S:750 E:760 ||| JJ
vasculitis  ||| S:760 E:771 ||| NN
of  ||| S:771 E:774 ||| IN
the  ||| S:774 E:778 ||| DT
central  ||| S:778 E:786 ||| JJ
nervous  ||| S:786 E:794 ||| JJ
system ||| S:794 E:800 ||| NN
.  ||| S:800 E:802 ||| .
Hence ||| S:802 E:807 ||| RB
,  ||| S:807 E:809 ||| ,
physicians  ||| S:809 E:820 ||| NNS
should  ||| S:820 E:827 ||| MD
be  ||| S:827 E:830 ||| VB
aware  ||| S:830 E:836 ||| JJ
of  ||| S:836 E:839 ||| IN
all  ||| S:839 E:843 ||| DT
alternative  ||| S:843 E:855 ||| JJ
diagnoses  ||| S:855 E:865 ||| NN
and  ||| S:865 E:869 ||| CC
PACNS  ||| S:869 E:875 ||| NNP
mimickers ||| S:875 E:884 ||| NN
,  ||| S:884 E:886 ||| ,
which  ||| S:886 E:892 ||| WDT
are  ||| S:892 E:896 ||| VBP
now  ||| S:896 E:900 ||| RB
well-known ||| S:900 E:910 ||| JJ
.  ||| S:910 E:912 ||| .
Whereas  ||| S:912 E:920 ||| IN
prognosis  ||| S:920 E:930 ||| VBG
now  ||| S:930 E:934 ||| RB
appears  ||| S:934 E:942 ||| VBZ
to  ||| S:942 E:945 ||| TO
be  ||| S:945 E:948 ||| VB
much  ||| S:948 E:953 ||| RB
better  ||| S:953 E:960 ||| JJR
than  ||| S:960 E:965 ||| IN
for  ||| S:965 E:969 ||| IN
the  ||| S:969 E:973 ||| DT
first  ||| S:973 E:979 ||| JJ
reported  ||| S:979 E:988 ||| JJ
cases ||| S:988 E:993 ||| NNS
,  ||| S:993 E:995 ||| ,
probably  ||| S:995 E:1004 ||| RB
attributable  ||| S:1004 E:1017 ||| JJ
to  ||| S:1017 E:1020 ||| TO
the  ||| S:1020 E:1024 ||| DT
use  ||| S:1024 E:1028 ||| NN
of  ||| S:1028 E:1031 ||| IN
corticosteroids  ||| S:1031 E:1047 ||| NN
and  ||| S:1047 E:1051 ||| CC
immunosuppressants ||| S:1051 E:1069 ||| NN
,  ||| S:1069 E:1071 ||| ,
mainly  ||| S:1071 E:1078 ||| RB
cyclophosphamide ||| S:1078 E:1094 ||| JJ
,  ||| S:1094 E:1096 ||| ,
the  ||| S:1096 E:1100 ||| DT
optimal  ||| S:1100 E:1108 ||| JJ
therapeutic  ||| S:1108 E:1120 ||| JJ
regimen ||| S:1120 E:1127 ||| NN
,  ||| S:1127 E:1129 ||| ,
potentially  ||| S:1129 E:1141 ||| RB
based  ||| S:1141 E:1147 ||| VBN
on  ||| S:1147 E:1150 ||| IN
each  ||| S:1150 E:1155 ||| DT
patient ||| S:1155 E:1162 ||| NN
's  ||| S:1162 E:1165 ||| POS
characteristics ||| S:1165 E:1180 ||| NNS
,  ||| S:1180 E:1182 ||| ,
and  ||| S:1182 E:1186 ||| CC
its  ||| S:1186 E:1190 ||| PRP$
duration  ||| S:1190 E:1199 ||| NNS
remain  ||| S:1199 E:1206 ||| VBP
to  ||| S:1206 E:1209 ||| TO
be  ||| S:1209 E:1212 ||| VB
determined ||| S:1212 E:1222 ||| VBN
.  ||| S:1222 E:1224 ||| .
Only  ||| S:1224 E:1229 ||| RB
multicenter  ||| S:1229 E:1241 ||| JJ
studies  ||| S:1241 E:1249 ||| NNS
and  ||| S:1249 E:1253 ||| CC
prospective  ||| S:1253 E:1265 ||| JJ
therapeutic  ||| S:1265 E:1277 ||| JJ
trials  ||| S:1277 E:1284 ||| NNS
will  ||| S:1284 E:1289 ||| MD
be  ||| S:1289 E:1292 ||| VB
able  ||| S:1292 E:1297 ||| JJ
to  ||| S:1297 E:1300 ||| TO
clarify  ||| S:1300 E:1308 ||| VB
these  ||| S:1308 E:1314 ||| DT
issues  ||| S:1314 E:1321 ||| NNS
on  ||| S:1321 E:1324 ||| IN
therapy  ||| S:1324 E:1332 ||| NN
and  ||| S:1332 E:1336 ||| CC
eventually  ||| S:1336 E:1347 ||| RB
provide  ||| S:1347 E:1355 ||| VB
some  ||| S:1355 E:1360 ||| DT
data  ||| S:1360 E:1365 ||| NNS
on  ||| S:1365 E:1368 ||| IN
PACNS  ||| S:1368 E:1374 ||| NNP
physiopathogenesis ||| S:1374 E:1392 ||| NN
,  ||| S:1392 E:1394 ||| ,
which  ||| S:1394 E:1400 ||| WDT
remains  ||| S:1400 E:1408 ||| VBZ
a  ||| S:1408 E:1410 ||| DT
poorly  ||| S:1410 E:1417 ||| RB
explored  ||| S:1417 E:1426 ||| JJ
domain ||| S:1426 E:1432 ||| NN
.  ||| S:1432 E:1434 ||| .
